viewRed Hat

Red Hat, AnaptysBio, Aimmune Therapeutics and more - AFTER HOURS

A look at the after hours trade in New York on Tuesday

A look at some highlights in after hours trade in New York

After stocks posted a higher finish on Wall Street, shares in Red Hat Inc (NYSE:RHT) added over 5% after the bell to US$161 on Monday.

The software group reported fourth quarter earnings per share (EPS) and revenue, which beat Wall Street expectations. Sales rose 23% year-on -year of US$772mln.

Meanwhile, AnaptysBio Inc (NASDAQ:ANAB) rose 8.79% in extended hours to US$123.83 after the drug developer announced positive peanut allergy treatment data yesterday.


Analysis of the mid-stage trial data pointed to nearly half of patients treated showing peanut tolerance.

Concurrently, fellow drug maker Aimmune Therapeutics Inc (NASDAQ:AIMT) shares dropped. Aimmune's drug to treat peanut allergy in children succeeded in a late-stage study in February.

Meanwhile, SM Energy Co (NYSE:SM) nudged 0.27% to US$18.62 after the bell after the natural gas explorer said it had completed its previously announced sale of the majority of its assets in the Powder River Basin for US$500mln.

The company plans to use the proceeds for general corporate purposes, including to reduce debt.

Quick facts: Red Hat


Price: - -

Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Destiny Pharma's hail 'win win deal' as China partner begins programme with...

Destiny Pharma PLC (AIM:DEST) (AIM:DEST) Neil Clark talks to Proactive London about their partner in China, Hong Kong listed China Medical System Holdings (HKG:0867) (HKG:0867) Ltd (CMS) launching a new programme aimed at delivering a new product using Destiny’s XF-73.  Their aim differs to...

5 hours, 4 minutes ago

2 min read